Caris Life Sciences®
Fulfilling the Promise of Personalized Medicine
Caris Life Sciences was founded because of an idea — that personalized and precise information can improve healthcare for everyone. This idea drives everything we do at Caris Life Sciences.
Caris combines the rigor of an academic medical institution with the innovative spirit of a technology company. We believe that innovative, high-quality testing and information can lead to more effective treatment selection and ultimately to better outcomes for patients with cancer and other complex diseases.
Caris Molecular Intelligence Service examines the genetic and molecular makeup that is unique to each patient’s tumor. By comparing the tumor's information with data from clinical studies from thousands of the world's leading cancer researchers, Caris provides treating oncologists information about which treatments are likely to be most effective and which treatments are likely to be ineffective for each patient.read more
Carisome is an innovative, proprietary and versatile testing technology that has the potential to reveal critical information about disease at its earliest stages, from a simple blood test. Currently being developed for a number of types of cancer including prostate, breast, lung and colorectal cancers, the technology has the potential to provide diagnostic, prognostic and theranostic information for patients throughout the continuum of care.read more
Since 1996, Caris Life Sciences has been a leader in diagnostic, prognostic and theranostic medicine. Our mission is to transform healthcare through development of innovative technologies.
Caris is a privately held leader in biosciences, headquartered in the Dallas-Fort Worth Metroplex, with additional operations in Phoenix, Arizona, and Basel, Switzerland.
“WE INTEND TO HELP RELIEVE THE SUFFERING OF AS MANY PEOPLE AS POSSIBLE”
David D. Halbert Chairman & CEO